Authorities would expect that companies define them more as potential signals than too quickly and easily as background noise.
As documented in GVP, Module IX – Signal management (Rev 1) https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf
, section X.B.5. Quality requirements: “Signal management is considered a critical process… Through a tracking system, all organisations should keep an audit trail of signal management activities, allowing traceability (i.e. recording of dates and confirmation of timeliness) and process control of the details of all steps of signal management, including analyses, decisions and rationale. “
It is therefore better to assume them as potential signals, track and manage them as per procedures with all related documentation. To classify them as background noise would need some other justifications outside of the drug.